ADELAIDE, Australia / RankWire.AI / – Scientists at Adelaide University and the Olivia Newton-John Cancer Research Institute have identified a molecular switch that influences the dissemination of aggressive tumors, opening a new therapeutic avenue to prevent secondary cancer development. Their study, published in EMBO Molecular Medicine, demonstrates that reactivating a crucial regulatory molecule called miR-342 substantially decreases tumor metastasis. These results suggest that Australian researchers are pioneering a novel approach to managing triple-negative breast cancer by targeting dormant cancer cells before they form lethal secondary tumors in distant organs.
Although triple-negative breast cancer accounts for 10% to 15% of the roughly 21,000 breast cancer cases diagnosed annually in Australia, it is responsible for a disproportionate number of fatalities. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, which makes standard hormone-based targeted therapies ineffective. The lead researchers showed that a decline in miR-342 levels activates a cancer-promoting pathway known as E2F, enabling dormant cancer cells to metastasize and develop secondary tumors across the body.
Targeted Drug Strategies Offer New Hope for Preventing High-Risk Metastasis
In experimental pre-clinical settings, the research team demonstrated that restoring miR-342 levels notably hindered the spread of cancer to distant organs. Additionally, they found that palbociclib, an existing CDK4/6 inhibitor drug approved for hormone receptor-positive breast cancers, effectively suppressed metastatic tumor growth in models with low miR-342 expression. These insights imply that evaluating miR-342 levels could enable clinicians to repurpose established therapies for patients at high risk of metastasis.
Associate Professor Philip Gregory, co-senior author from Adelaide University’s Centre for Cancer Biology, highlighted that preventing metastasis remains a key challenge in managing aggressive breast cancers. He emphasized that because palbociclib targets the overactive E2F pathway, administering it after cancer cells have spread can prevent the expansion of microscopic deposits. Instead of only reducing primary tumor size, this approach aims to stop tiny secondary tumors from progressing into life-threatening conditions.
Pre-Clinical Data Published in Peer-Reviewed EMBO Molecular Medicine
The research team pointed out that the biological diversity of triple-negative breast cancer has historically hampered the development of universal targeted therapies. Identifying a specific biological vulnerability common to a certain patient subgroup presents opportunities for personalized treatments. As Australian scientists advance this promising strategy, plans are underway to validate their findings in patient-derived models before moving into clinical trials.
Cancer specialists and research organizations across Australia have welcomed the discovery, emphasizing the critical need for expanding therapeutic options when primary treatments fail. The team intends to work with global clinical networks to speed up biomarker screening procedures. Confirming the utility of miR-342 testing could soon enable doctors to identify suitable patients for early targeted intervention with CDK4/6 inhibitors.